exenatide
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Complications
Conditions
Diabetes Complications, Fatty Liver
Trial Timeline
Oct 1, 2007 → Feb 1, 2010
NCT ID
NCT00529204About exenatide
exenatide is a phase 2 stage product being developed by Eli Lilly for Diabetes Complications. The current trial status is terminated. This product is registered under clinical trial identifier NCT00529204. Target conditions include Diabetes Complications, Fatty Liver.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Complications were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01373216 | Phase 3 | Completed |
| NCT01056549 | Pre-clinical | Completed |
| NCT00753896 | Phase 3 | Completed |
| NCT00529204 | Phase 2 | Terminated |
| NCT00516048 | Phase 3 | Completed |
| NCT01876849 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Complications